Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
3 "Ik-Chan Song"
Filter
Filter
Article category
Keywords
Publication year
Authors
Original Articles
The Efficacy and Safety of Platinum/Vinorelbine as More Than Second-Line Chemotherapy for Advanced Non-small Cell Lung Cancer
Ik-Chan Song, Hyo-Jin Lee, Young-Jun Yang, Yoon-Seok Choi, Hye-Won Ryu, Myung-Won Lee, Ji Young Moon, Deog-Yeon Jo, Samyong Kim, Hwan-Jung Yun
Cancer Res Treat. 2015;47(4):638-644.   Published online March 2, 2015
DOI: https://doi.org/10.4143/crt.2014.316
AbstractAbstract PDFPubReaderePub
Purpose
There is no regimen that is strongly recommended for more than second-line treatment. We investigated the efficacy and safety of platinum/vinorelbine as more than second-line treatment. Materials and Methods We selected patients with advanced non-small cell lung cancer (NSCLC) who received treatment with platinum/vinorelbine at Chungnam National University Hospital from August 2001 to December 2013. The primary end point was the response rate, and secondary end points were progression-free survival (PFS), overall survival (OS), and toxicity.
Results
Thirty-five patients were enrolled. Response rate was 22.9% (complete response, 0 patients [0%]; partial response, eight patients [22.9%]; stable disease, 10 patients [28.6%]; progressive disease, 14 patients [40.0%]). A significantly higher response rate was observed for patients who had responded to previous chemotherapy than for those who did not (34.8% [8/23] vs. 0% [0/12], p=0.020). The median PFS was 4 months (range, 1 to 21 months). Patients with adenocarcinoma and non-smokers had a significantly longer PFS than patients with non-adenocarcinoma and smokers (5 months vs. 2 months, p=0.007; 4.5 months vs. 2 months, p=0.046, respectively). The median OS was 10 months (range, 1 to 41 months). Patients with good performance status and non-smokers had a significantly longer OS than patients with poor performance status and smokers (14 months vs. 4 months, p=0.02; 18.5 months vs. 6 months, p=0.049, respectively). The main serious adverse event (grade 3 or 4) was neutropenia (15 events, 13.3%) in a total of 113 cycles. Conclusion Platinum/vinorelbine was effective as more than second-line chemotherapy, and the toxicity was tolerable, in patients with advanced NSCLC.
  • 12,007 View
  • 61 Download
Close layer
Diagnostic and Prognostic Implications of Spine Magnetic Resonance Imaging at Diagnosis in Patients with Multiple Myeloma
Ik-Chan Song, Ji-Na Kim, Yoon-Seok Choi, Haewon Ryu, Myung-Won Lee, Hyo-Jin Lee, Hwan-Jung Yun, Samyong Kim, Soon Tae Kwon, Deog-Yeon Jo
Cancer Res Treat. 2015;47(3):465-472.   Published online November 3, 2014
DOI: https://doi.org/10.4143/crt.2014.010
AbstractAbstract PDFPubReaderePub
Purpose
The aim of this study is to determine the diagnostic and prognostic role of baseline spinal magnetic resonance imaging (MRI) in patients with multiple myeloma.
Materials and Methods
We enrolled patients newly diagnosed with multiple myeloma from 2004-2011 at a single center. Abnormal MRI findings that were not detected in radiographs have been analyzed and categorized as malignant compression fractures or extramedullary plasmacytoma. The bone marrow (BM) infiltration patterns on MRI have been classified into five categories.
Results
A total of 113 patients with a median age of 65 years (range, 40 to 89 years) were enrolled in the study. Malignant compression fractures not detected in the bone survey were found in 26 patients (23.0%), including three patients (2.6%) with no related symptoms or signs. Extramedullary plasmacytoma was detected in 22 patients (19.5%), including 15 (13.3%) with epidural extension of the tumor. Of these 22 patients, 11 (50.0%) had no relevant symptoms or signs. The presence of malignant compression fractures did not influence overall survival; whereas non-epidural extramedullary plasmacytoma was associated with poor overall survival in the multivariate analysis (hazard ratio, 3.205; 95% confidence interval [CI], 1.430 to 9.845; p=0.042). During the follow-up for a median of 21 months (range, 1 to 91 months), overall survival with the mixed BM infiltrative pattern (median, 24.0 months; 95% CI, 22.9 to 25.1 months) was shorter than those with other patterns (median 56 months; 95% CI, 48.9 to 63.1 months; p=0.030).
Conclusion
These results indicate that spine MRI at the time of diagnosis is useful for detecting skeletal lesions and predicting the prognosis in patients with multiple myeloma.

Citations

Citations to this article as recorded by  
  • Prognostic significance of extramedullary disease (EMD) detected on pre-transplant 18F-FDG PET/CT in patients with multiple myeloma: Results of PIPET-M trial
    Uday Yanamandra, Arun Kumar Reddy Gorla, Kanhaiyalal Agrawal, Bhagwant Rai Mittal, Gaurav Prakash, Alka Rani Khadwal, Neelam Varma, Subhash Varma, Pankaj Malhotra
    Medical Journal Armed Forces India.2023; 79(6): 672.     CrossRef
  • Clinical impact of spine magnetic resonance imaging as a valuable prognostic tool for patients with multiple myeloma: a retrospective study
    Jung Min Lee, Hee Jeong Cho, Joon-Ho Moon, Sang Kyun Sohn, Byunggeon Park, Dong Won Baek
    Journal of Yeungnam Medical Science.2022; 39(4): 300.     CrossRef
  • Diagnostic value of whole-body ultra-low dose computed tomography in comparison with spinal magnetic resonance imaging in the assessment of disease in multiple myeloma
    Davide Ippolito, Cammillo Talei Franzesi, Sara Spiga, Valeria Besostri, Sara Pezzati, Fausto Rossini, Sandro Sironi
    British Journal of Haematology.2017; 177(3): 395.     CrossRef
  • Automated “Bone Subtraction” Image Analysis Software Package for Improved and Faster CT Monitoring of Longitudinal Spine Involvement in Patients with Multiple Myeloma
    Marius Horger, Hendrick Ditt, Shu Liao, Katja Weisel, Jan Fritz, Wolfgang M. Thaiss, Sascha Kaufmann, Konstantin Nikolaou, Christopher Kloth
    Academic Radiology.2017; 24(5): 623.     CrossRef
  • Multimodality imaging of osseous involvement In haematological malignancies
    Abhishek R Keraliya, Katherine M Krajewski, Jyothi P Jagannathan, Atul B Shinagare, Marta Braschi-Amirfarzan, Sree H Tirumani, Nikhil H Ramaiya
    The British Journal of Radiology.2016; 89(1059): 20150980.     CrossRef
  • Risk Stratification in Multiple Myeloma
    Melissa Gaik-Ming Ooi, Sanjay de Mel, Wee Joo Chng
    Current Hematologic Malignancy Reports.2016; 11(2): 137.     CrossRef
  • Temporomandibular joint involvement in patients with multiple myeloma—a retrospective study
    W. Abboud, R. Yahalom, M. Leiba, G. Greenberg, N. Yarom
    International Journal of Oral and Maxillofacial Surgery.2016; 45(12): 1545.     CrossRef
  • 18,416 View
  • 124 Download
  • 7 Web of Science
  • 7 Crossref
Close layer
Cytoplasmic Trapping of CXCR4 in Hepatocellular Carcinoma Cell Lines
Seong-Woo Kim, Ha-Yon Kim, Ik-Chan Song, Seon-Ah Jin, Hyo-Jin Lee, Hwan-Jung Yun, Samyong Kim, Deog-Yeon Jo
Cancer Res Treat. 2008;40(2):53-61.   Published online June 30, 2008
DOI: https://doi.org/10.4143/crt.2008.40.2.53
AbstractAbstract PDFPubReaderePub
Purpose

The chemokine receptor CXCR4 plays a role in the metastasis and progression of a broad range of malignant tumors; however, its influence on hepatocellular carcinoma (HCC) is not well defined. Thus, we analyzed the expression of CXCR4 and its functions in HCC cell lines in vitro.

Materials and Methods

Five HCC cell lines (HepG2, Hep3B, SK-HEP-1, NCI-H630 and PLC/PRF5) were investigated. The CXCR4 expression was analyzed by RT-PCR, Western blotting, flow cytometry and immunofluorescence staining. In addition, the effects of stromal cell-derived factor-1 (SDF-1) on the migration, proliferation and survival of the cells were investigated, as well as the SDF-1-induced phosphorylation of signaling molecules.

Results

All five cell lines had abundant CXCR4 in their cytoplasm, whereas a cell surface CXCR4 expression was only detected in a very small population of PLC/PRF5 cells. In contrast, SDF-1 bound to all the cells. SDF-1 induced the phosphorylation of AKT and ERK1/2 in the PLC/PRF5 cells and the phosphorylation of Stat3, AKT and ERK1/2 in the Hep3B cells. Nonetheless, SDF-1 did not induce migration or proliferation in any of the cells, nor did it rescue the cells from serum deprivation-induced apoptosis. Recruitment of CXCR4 from the cytoplasm to the cell surface was not elicited by dexamethasone, proinflammatory cytokines or VEGF. Hypoxia increased both the cytoplasmic and cell surface expressions of CXCR4 in only the PLC/PRF5 cells.

Conclusions

CXCR4 is trapped in the cytoplasm and it is not recruited to the cell surface by standard extrinsic stimuli in the majority of HCC cell lines, and the result of this is a negligible response to SDF-1.

Citations

Citations to this article as recorded by  
  • CXCR4, regulated by HIF1A, promotes endometrial breakdown via CD45+ leukocyte recruitment in a mouse model of menstruation
    Shufang Wang, Xihua Chen, Shige Guo, Fang Zhou, Xin Zhang, Cong Lu, Xuqing Yang, Qianxing Wang, Bin He, Jiedong Wang, Hanbi Wang, Xiangbo Xu
    Reproductive Biology.2023; 23(3): 100785.     CrossRef
  • Interaction of immune checkpoint PD-1 and chemokine receptor 4 (CXCR4) promotes a malignant phenotype in pancreatic cancer cells
    Megan M. Harper, Miranda Lin, Michael J. Cavnar, Prakash K. Pandalai, Reema A. Patel, Mei Gao, Joseph Kim, Ming Tan
    PLOS ONE.2022; 17(7): e0270832.     CrossRef
  • The Effect of Hypoxia on the Expression of CXC Chemokines and CXC Chemokine Receptors—A Review of Literature
    Jan Korbecki, Klaudyna Kojder, Patrycja Kapczuk, Patrycja Kupnicka, Barbara Gawrońska-Szklarz, Izabela Gutowska, Dariusz Chlubek, Irena Baranowska-Bosiacka
    International Journal of Molecular Sciences.2021; 22(2): 843.     CrossRef
  • Somatostatin and CXCR4 chemokine receptor expression in hepatocellular and cholangiocellular carcinomas: tumor capillaries as promising targets
    Daniel Kaemmerer, Robin Schindler, Franziska Mußbach, Uta Dahmen, Annelore Altendorf-Hofmann, Olaf Dirsch, Jörg Sänger, Stefan Schulz, Amelie Lupp
    BMC Cancer.2017;[Epub]     CrossRef
  • Role of C-X-C chemokine ligand 12/C-X-C chemokine receptor 4 in the progression of hepatocellular carcinoma
    Kuo-Shyang Jeng, Chi-Juei Jeng, Wen-Juei Jeng, Chiung-Fang Chang, I-Shyan Sheen
    Oncology Letters.2017; 14(2): 1905.     CrossRef
  • An Ultra‐High Fluorescence Enhancement and High Throughput Assay for Revealing Expression and Internalization of Chemokine Receptor CXCR4
    Hua He, Xiaojuan Wang, Tiantian Cheng, Yongqing Xia, Jun Lao, Baosheng Ge, Hao Ren, Naseer Ullah Khan, Fang Huang
    Chemistry – A European Journal.2016; 22(17): 5863.     CrossRef
  • CXCR4 expression affects overall survival of HCC patients whereas CXCR7 expression does not
    Maria Neve Polimeno, Caterina Ierano, Crescenzo D'Alterio, Nunzia Simona Losito, Maria Napolitano, Luigi Portella, Giosuè Scognamiglio, Fabiana Tatangelo, Anna Maria Trotta, Steven Curley, Susan Costantini, Raffaele Liuzzi, Francesco Izzo, Stefania Scala
    Cellular & Molecular Immunology.2015; 12(4): 474.     CrossRef
  • Mechanisms regulating cell membrane localization of the chemokine receptor CXCR4 in human hepatocarcinoma cells
    Edgar B. Cepeda, Tatjana Dediulia, Joan Fernando, Esther Bertran, Gustavo Egea, Estanislao Navarro, Isabel Fabregat
    Biochimica et Biophysica Acta (BBA) - Molecular Cell Research.2015; 1853(5): 1205.     CrossRef
  • Immunohistochemical Expression of CXCR4 on Breast Cancer and Its Clinical Significance
    Marina Okuyama Kishima, Carlos Eduardo Coral de Oliveira, Bruna Karina Banin-Hirata, Roberta Losi-Guembarovski, Karen Brajão de Oliveira, Marla Karine Amarante, Maria Angelica Ehara Watanabe
    Analytical Cellular Pathology.2015; 2015: 1.     CrossRef
  • Intracellular coexpression of CXC- and CC– chemokine receptors and their ligands in human melanoma cell lines and dynamic variations after xenotransplantation
    Sandra Pinto, Alicia Martínez-Romero, José-Enrique O’Connor, Rosario Gil-Benso, Teresa San-Miguel, Liria Terrádez, Carlos Monteagudo, Robert C Callaghan
    BMC Cancer.2014;[Epub]     CrossRef
  • Intracellular trafficking and endocytosis of CXCR4 in fetal mesenchymal stem/stromal cells
    Rebecca A Pelekanos, Michael J Ting, Varda S Sardesai, Jennifer M Ryan, Yaw-Chyn Lim, Jerry KY Chan, Nicholas M Fisk
    BMC Cell Biology.2014;[Epub]     CrossRef
  • Downregulation of the proangiogenic prostaglandin E receptor EP3 and reduced angiogenesis in a mouse model of diabetes mellitus
    Kazuhito Oba, Kanako Hosono, Hideki Amano, Shin-ichiro Okizaki, Yoshiya Ito, Masayoshi Shichiri, Masataka Majima
    Biomedicine & Pharmacotherapy.2014; 68(8): 1125.     CrossRef
  • Tacrolimus promotes hepatocellular carcinoma and enhances CXCR4/SDF-1α expression in vivo
    HUAQI ZHU, QIMAN SUN, CHANGJUN TAN, MIN XU, ZHI DAI, ZHENG WANG, JIA FAN, JIAN ZHOU
    Molecular Medicine Reports.2014; 10(2): 585.     CrossRef
  • Histone deacetylase inhibitors induce CXCR4 mRNA but antagonize CXCR4 migration
    Caterina Ierano, Agnes Basseville, Kenneth K.W. To, Zhirong Zhan, Robert W. Robey, Julia Wilkerson, Susan E. Bates, Stefania Scala
    Cancer Biology & Therapy.2013; 14(2): 175.     CrossRef
  • 11,222 View
  • 60 Download
  • 14 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP